



Appendix

This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Appendix to: Sinha YK, Craig JC, Barclay PG, et al. A national study of the processes and outcomes of paediatric formulary applications in Australia. *Med J Aust* 2014; 200: 541-545. doi: 10.5694/mja13.11138.

Appendix 1. Formulary applications for new drugs or indications and number of hospitals that reviewed them (in brackets)

Anatomic therapeutic chemical classification*	Formulary applications
A. Alimentary tract	Pyridoxal-5-phosphate(1), calcium phosphate(1), macrogol 3350(2), calcium carbonate(1), sodium picosulfate(1), tropisetron(1), insulin glulisine(1)
B. Blood, C. Cardiovascular	Aprotinin(1), renal replacement solutions (Prismocal®(2), Prismocitrate 10/2®(2)), SMOFlipid® 20% (1), epoprostenol(1), <i>balance peritoneal dialysis fluid</i> †(1), celiprolol(1)
D. Dermatologicals	Ethanol 70%(1)
G. Genito-urinary; H: Hormonal	Oestradiol valerate§(1), <i>Deflazacort</i> (1), testosterone undecanoate§(2), desmopressin(1)
J. Anti-infectives; P. Antiparasitic	Piperacillin/tazobactam(1), tobramycin(2), human immunoglobulin(1), doxycycline(1), <i>doxycycline</i> †(1), lincomycin(2), palivizumab(1), <i>palivizumab</i> (1)
L. Antineoplastic, immunomodulating	IV busulfan¶(1), goserelin§(2), sirolimus(1), <i>sirolimus</i> †(1), mTOR inhibitors(1), pegasparginase(1), <i>bevacizumab</i> †(1), mycophenolate(4), tacrolimus(2), adalimumab(1), clofarabine(1), imatinib(1), leuporelin(1), <i>mitomycin C</i> (1)
M. Musculoskeletal	<i>Botulinum toxin (Dysport®)</i> (1), <i>Bisphosphonates</i> (1), zoledronic acid(1), IV parecoxib(1), mivacurium chloride(1)
N. Nervous system	IV lacosamide(3), PO lacosamide(3), lacosamide(1)‡, lignocaine 4% (LMX4®)(4), olanzapine(1), <i>olanzapine</i> †(1), escitalopram(2), rufinamide(1), zonisamide(1), ziprasidone(1), <i>ziprasidone</i> (1), <i>lorazepam</i> (2), PO paliperidone(1), inj paliperidone(1), IV paracetamol(1), methylphenidate(1), propofol-lipuro®(1), <i>stiripentol</i> (1), levetiracetam(1), levomepromazine(1), quetiapine(1)
R. Respiratory	Ephedrine(1), <i>cyclizine</i> (1), mannitol(1), montelukast(1)
V. Various; X. Not classified	Taurine(1), omega 3 fatty acids(1), vapocoolant spray (Pain Ease®)(1), sugammadex(1), MCT Peptide 1+®(1), diphenylcyclopropenone(1)
Total: 97 drugs, 95 applications (80/95, 84% accepted)	

Rejected or deferred applications in italics; number of hospitals that reviewed them (brackets)

* Titles abbreviated for ATC categories A to V. Full titles available from <http://www.whooc.no/atcddd/>

† Deferred applications, ‡ Route of administration for lacosamide not specified by applicant.

§ Application for testosterone undecanoate, goserelin and oestradiol valerate was submitted as a joint application for “hormonal treatment for transgender patients” so total number of applications is 95. ¶ Replaced oral busulfan. Reviewed by committee as a major submission with supporting data.